Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.

Schmidt-Erfurth U., Eldem B., Guymer R., Korobelnik J.F., Schlingemann R.O., Axer-Siegel R., Wiedemann P., Simader C., Gekkieva M., Weichselberger A.; EXCITE Study Group

Ophthalmology. 2011;118(5):831-9.

2011

Validation of Retmarker AMD for Quantification of Early Age-Related Maculopathy Features.

Validation of Retmarker AMD for Quantification of Early Age-Related Maculopathy Features.

Validation of Retmarker AMD for Quantification of Early Age-Related Maculopathy Features.

Simao S.N., Nunes S., Vilhena N., Cachulo M.L., Faria de Abreu J., Cunha-Vaz J., Silva R.

Invest Ophthalmol Vis Sci 2011;52: 94.

2011

A Phase 2/3, Multicentre, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema.

A Phase 2/3, Multicentre, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema.

A Phase 2/3, Multicentre, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema.

Sultan M., Zhou D., Loftus J. et al, for the Macugen 1013 Study Group.

Ophthalmology 2011;118:1107-1118.

2011

Biological and Medical Physics, Biomedical Engineering. Optical Coherence Tomography: A Clinical and Technical Update.

Biological and Medical Physics, Biomedical Engineering. Optical Coherence Tomography: A Clinical and Technical Update.

Biological and Medical Physics, Biomedical Engineering. Optical Coherence Tomography: A Clinical and Technical Update.

Bernardes R., Cunha-Vaz J. (ed.)

Springer, 2012

2012

Retinal thickness with HD-OCT is not a surrogate outcome for visual acuity changes in diabetic macular edema.

Retinal thickness with HD-OCT is not a surrogate outcome for visual acuity changes in diabetic macular edema.

Retinal thickness with HD-OCT is not a surrogate outcome for visual acuity changes in diabetic macular edema.

Nunes S., Pereira I., Santos A., Bernardes R., Cunha-Vaz J.

BMJ Pub. Group, 2010, 94

2010

Validation of a predictive model for diabetic retinopathy progression in type-2 diabetic patients with mild nonproliferative diabetic retinopathy.

Validation of a predictive model for diabetic retinopathy progression in type-2 diabetic patients with mild nonproliferative diabetic retinopathy.

Validation of a predictive model for diabetic retinopathy progression in type-2 diabetic patients with mild nonproliferative diabetic retinopathy.

Nunes S., Bernardes R., Lobo C., Cunha-Vaz J.

Acta Ophthalmologica – Special Issue: Abstracts from the 2009 European Association for Vision and Eye Research Conference, 2009, 87, S244, 0

2009

High-definition Fourier domain OCT: non-invasive assessment of BRB changes.

High-definition Fourier domain OCT: non-invasive assessment of BRB changes.

High-definition Fourier domain OCT: non-invasive assessment of BRB changes.

Bernardes R., Santos T., Cunha-Vaz J.

Acta Ophthalmologica – Special Issue: Abstracts from the 2009 European Association for Vision and Eye Research Conference, 2009, 87, S244, 0

2009

Semi-automated assessment of microaneurysm formation rate from color fundus photographs in patients with mild NPDR.

Semi-automated assessment of microaneurysm formation rate from color fundus photographs in patients with mild NPDR.

Semi-automated assessment of microaneurysm formation rate from color fundus photographs in patients with mild NPDR.

Bernardes R., Nunes S., Pereira I., Lobo C., Cunha-Vaz J.

Acta Ophthalmologica – Special Issue: Abstracts from the 2009 European Association for Vision and Eye Research Conference, 2009, 87, S244, 0

2009

Risk markers for progression of mild nonproliferative retinopathy to clinically significant macular edema in type 2 diabetic patient.

Risk markers for progression of mild nonproliferative retinopathy to clinically significant macular edema in type 2 diabetic patient.

Risk markers for progression of mild nonproliferative retinopathy to clinically significant macular edema in type 2 diabetic patient.

Pereira I., Nunes S., Ribeiro M., Bernardes R., Cunha-Vaz J.

Acta Ophthalmologica – Special Issue: Abstracts from the 2008 European Association for Vision and Eye Research Conference, 2008, 86, S243, 0

2008